Northland (920047) uses 48 million yuan of its own funds and 40 million yuan of raised funds to purchase bank wealth management products to improve capital utilization efficiency

On March 9th, Beijing Northland Biotechnology Co., Ltd. announced that the total amount of entrusted wealth management using idle self-owned funds is 48 million yuan, and the total amount of cash management using idle raised funds is 40 million yuan. As of now, the company’s unused balance of entrusted wealth management with idle self-owned funds is 75.9 million yuan, and the unused balance of cash management with idle raised funds is 40 million yuan.

Northland stated in the announcement that in order to improve the utilization rate of the company’s idle funds and increase investment returns, without affecting the normal development of the company’s main business and ensuring the company’s operational needs, the company plans to use no more than 100 million yuan of idle self-owned funds to purchase high-security, highly liquid financial products, and no more than 100 million yuan of idle raised funds for the same purpose.

According to industry sources, the company is an innovative biopharmaceutical enterprise specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic medicines. The company adheres to the mission of “creating value, serving health,” and focuses on clinical needs, mainly dedicated to the research and industrialization of new biological engineering drugs for cardiovascular diseases, metabolic diseases, rare diseases, and ophthalmic diseases, providing safe, effective, and quality-controlled drugs for disease treatment.

With over twenty years of experience in the biopharmaceutical industry, the company has accumulated rich drug R&D experience, developed a diverse and industry-specific pipeline of gene therapy and recombinant protein drugs, and owns multiple independent intellectual property rights for biopharmaceuticals. It has obtained over 30 patents, and has been recognized as a national high-tech enterprise, a Beijing science and technology R&D institution, a Beijing “Naked Plasmid Engineering Technology Center,” and a “Specialized, Refined, and Innovative” small and medium-sized enterprise. The company has an independent technical system and comprehensive capabilities for drug screening, pharmaceutical research, clinical research, and process scale-up, and has established a mature platform for biopharmaceutical R&D and manufacturing. It masters core technologies such as gene vector construction, engineered bacteria construction, microbial expression, mammalian cell expression, biopharmaceutical production processes, large-scale manufacturing techniques, and eye drop development. Currently, relying on core independent technologies and a self-built ophthalmic drug production workshop through its subsidiaries, the company can carry out drug R&D, production, sales, technology transfer, technical services, and entrusted processing.

In the field of innovative biopharmaceuticals, the current R&D pipeline includes 11 projects, with 5 gene therapy drugs and 6 recombinant protein drugs. The core product “Sedomin Injection” (project code: NL003) has completed Phase III clinical trials and submitted a registration application for ulcer indications. Other innovative drug projects are at Phase III, Phase II, or preclinical research stages. Regarding ophthalmic medicines, the company and its secondary subsidiary Hui Enland hold a total of 8 eye drop product registration approvals. Hui Enland has built three GMP-certified production lines (single-dose, multi-dose, rinse) in Tongzhou District, Beijing, and has completed the construction of an additional single-dose production line (Line 04), which has passed GMP certification by the Beijing Drug Review and Inspection Center. Using industry-leading “blow, fill, seal” integrated sterile automatic production technology for eye drops, the main products cover indications such as anti-bacterial, anti-allergy, dry eye, and glaucoma. The company is gradually developing and enriching its ophthalmic product pipeline around these areas.

In terms of performance, in the first three quarters of 2025, the company achieved operating revenue of 52.62 million yuan, with a net profit attributable to shareholders of listed companies of -36.81 million yuan.